Crespi J, Bratbak D, Dodick DW, et al. - Whether it is safe to inject onabotulinumtoxin A (BTA) toward the otic ganglion (OG) in patients (n = 10) with intractable chronic cluster headache was examined in this open‐label, multi‐dose pilot safety study and efficacy data were also collected. Recruitment of all patients as well as their management on an out‐patient basis at St Olav's University Hospital (Norway) was done. In 5 patients each, the OG was the injection target with 12.5 IU of BTA or 25 IU, respectively. Adverse events as well as the number of attacks per week determined at baseline as well as in the second month after injection were evaluated. Findings are suggestive of the safety of injection with BTA toward the OG. Relative to the baseline, no statistically significant decrease in the number of attacks per week was evident at month 2 post-injection. Based on these data, OG is refuted as a crucial target for the management of chronic cluster headache.